#USA #Chicago #CAR-T therapy #AbelZeta #ACR Convergence

AbelZeta's Groundbreaking CAR-T Therapy Presentation at ACR Convergence 2025

AbelZeta Pharma, Inc., a leading global biotech company, is set to present groundbreaking clinical data during the upcoming ACR Convergence 2025, scheduled to take place from October 24 to 29, 2025, at McCormick Place in Chicago, Illinois. This presentation will feature results from its first-in-human Phase I trial of C-CAR168, an innovative CAR-T therapy developed specifically for patients suffering from refractory autoimmune diseases.

Overview of the Therapy

C-CAR168 is a bispecific Chimeric Antigen Receptor T-cell (CAR-T) therapy that targets both CD20 and BCMA. Its dual action is designed to specifically identify and attack autoantibody-producing plasma cells and their B-cell precursors, aiming to achieve what is referred to as an "immune reset." This strategic approach could potentially lead to sustained drug-free remission for individuals battling challenging autoimmune disorders.

Presentation Details

During the conference, AbelZeta will conduct a late-breaking poster presentation that aims to draw attention to the promising outcomes observed in the trial participants. The presentation will take place on October 28, 2025 from 10:30 AM to 12:30 PM CT in Hall F1 at McCormick Place. The abstract that will be presented bears the ID 2211304 and is titled, "Anti-CD20/BCMA Bispecific CAR-T Cell Therapy Promotes Immune Reset and Sustained Drug Free Remission in Refractory Autoimmune Diseases."

The Importance of ACR Convergence

ACR Convergence is one of the most prestigious gatherings for professionals in the rheumatology field. Attendees include researchers, physicians, and stakeholders who are eager to learn about the latest advancements in treatments and interventions for autoimmune disorders. AbelZeta’s participation marks a significant contribution to the dialogue surrounding innovative therapies for hard-to-treat conditions.

About AbelZeta Pharma

Founded with the goal of revolutionizing treatment approaches, AbelZeta is committed to the discovery and development of tailored therapies that engage the body’s immune system in combating various diseases, particularly in the fields of hematological cancers and autoimmune disorders. Their state-of-the-art facilities located in Rockville, Maryland, and Shanghai, China, enhance their capabilities in research and early-stage clinical trials.

The company prides itself on a robust pipeline of CAR-T therapies, reinforcing its role as a pioneer in the biopharmaceutical landscape. AbelZeta is dedicated to utilizing its proprietary cell-based therapy platforms to provide hope to patients facing debilitating conditions where conventional treatments have failed.

Moving Forward

As AbelZeta prepares to share its findings at ACR Convergence 2025, there is a palpable sense of excitement within the biopharmaceutical community. The potential to not only advance medical understanding but also change patients’ lives promises to be a key theme throughout the presentation. This event will be crucial in shaping the future of autoimmune disease treatments, with AbelZeta at the forefront.

Conclusion

AbelZeta’s presentation at ACR Convergence 2025 is positioned to be a landmark moment not just for the company but also for patients striving for relief from refractory autoimmune diseases. As clinical data becomes available, the hope is that C-CAR168 will offer new avenues for treatment where none currently exist, steering the field toward innovative solutions that prioritize patient outcomes.